What CORZ Options Know That the Stock Price Doesn’t

Start with the options market, not the stock. That is always the right order.

On July 28, the day Core Scientific (NASDAQ: CORZ) dropped its Q2 earnings alongside a 15-year AMD partnership worth more than $14 billion in base contracted revenue, something specific happened in the options market. Traders acquired 141,404 call options in a single session. That is approximately 55% above the typical daily call volume of around 91,193 contracts. Total options volume across the day reached levels that translated to roughly 19.7 million underlying share equivalents, approximately 155% of the stock’s 30-day average daily share volume. That is not noise. That is directional interest being expressed through derivatives at a scale that exceeds what was visible in the equity market itself.

The stock closed near $20.72. Down roughly 32% from its 52-week high of $30.46. And the calls kept coming.

That divergence, between a falling stock and surging call activity, is the signal worth examining. It does not mean the market is wrong. It means different participants are reading the same information and arriving at very different conclusions about what comes next. When call volume runs 55% above average on the same day an equity sells off after a revenue beat, the derivatives market is surfacing a disagreement worth understanding.

Why Sophisticated Participants Are Paying Attention

Here is what the options flow is reflecting. CORZ has a beta of 5.50. That is not a typo. The stock moves with an amplitude that makes standard position sizing irrelevant for most equity portfolios. A 5.50 beta means that in a week where the broader market moves 2%, CORZ can realistically move 10 to 11 points in either direction. For traders who want exposure to the AI infrastructure thesis without sizing into full equity risk, the options market on a stock with this beta is genuinely useful. Defined-risk call structures let you participate in a rerating event with a fixed maximum loss. That asymmetry is exactly what elevated call activity looks like from the outside.

There is also the IV30 context to consider. In the days around the earnings release, implied volatility on CORZ was running above its 52-week median. One pre-earnings reading showed IV30 near 86.2, above the 52-week median, with an expected daily move of approximately $1.09. That is a meaningful premium over realized volatility, and it reflects genuine uncertainty about two things: the construction timeline, and the broader question of whether the market will begin valuing this stock as an AI infrastructure platform rather than a Bitcoin miner with ambitions.

The put/call structure has been shifting. Earlier in June, a separate session showed put/call ratio near 0.59 versus a typical level of 0.35, with options volume nearly triple the daily average and put-call skew flattening toward a modestly bullish tone. That was before the AMD deal was announced. The call surge on July 28 suggests the composition of that positioning has continued to evolve. Calls are leading puts. Skew has been compressing. These are not signs of a market bracing for collapse.

The Company Behind the Signal

The fundamentals are worth understanding clearly, because the GAAP numbers create confusion that the options market appears to be looking through.

Core Scientific reported Q2 2026 revenue of $164.2 million, beating analyst consensus of approximately $144.83 million by about $19 million. That is a 109% increase from $78.6 million in Q2 2025. Colocation revenue reached $136.7 million for the quarter, up from $10.6 million in the same period one year ago. That is a 1,190% increase year over year in the division that now runs the company. Adjusted EBITDA came in at $41.1 million, up from $28.5 million in Q2 2025. Gross profit was $70 million on a 59% colocation margin and a 43% consolidated margin. The company ended Q2 with $1.8 billion in liquidity.

The GAAP net loss for Q2 was approximately $1.2 billion, driven primarily by warrant fair value changes and a $266.5 million mining asset impairment. Neither of those is a cash event. Strip them out and the operating business is growing adjusted EBITDA with revenue running at more than double the prior year pace. The GAAP loss is an accounting artifact of two things: a derivatives-heavy capital structure and the deliberate destruction of a legacy business that is being replaced by something structurally more valuable.

The AMD deal is the part that changes the long-term math. Core Scientific signed 15-year agreements covering approximately 530 megawatts across five U.S. sites, generating more than $14 billion in base contracted revenue with 2.5% annual escalators. AMD also received warrants to purchase up to 30 million CORZ shares at $23.47. The option structure matters: AMD secured the right to reserve up to an additional 1,925 megawatts of capacity through December 2028, which could push the partnership toward 2.5 gigawatts total. When combined with the existing CoreWeave contract covering roughly 590 megawatts, total leased customer power capacity has reached 1.1 gigawatts, representing over $24 billion in base contracted revenue.

Slight tangent, but it matters for understanding why this deal happened here specifically. AMD needed physical infrastructure, not just chips. Grid-connected land with substations already tied to the utility system and fiber already in the ground is not a commodity you replicate quickly. Morgan Stanley’s research put the broader problem in focus: U.S. data centers will need 68 gigawatts of power between 2026 and 2028, projects under construction account for roughly 15 gigawatts, and available or contracted utility capacity covers another 15 gigawatts. That leaves a potential 38-gigawatt shortfall. Grid interconnection queues in some regions already stretch five to seven years. Bitcoin mining companies, with nearly 20 gigawatts across grid-connected sites, can deliver repurposed capacity one to three years faster than waiting for utilities. Core Scientific had the land, the connections, and the track record. That is the only reason the AMD deal exists where it does.

What the Market Appears to Be Pricing In

At roughly $20.72, Core Scientific carries a market cap near $6.6 billion against $24 billion-plus in base contracted backlog. The street consensus sits around $29 to $30 per share, with recent targets from Needham at $35, Canaccord at $36, and Freedom Capital at $33 with a Strong Buy rating. That implies roughly 40 to 50% upside from current levels based on analyst models.

The options market is not simply repricing the stock on this news. It is pricing the uncertainty between two very different outcomes. On the bullish side: 437 megawatts of CoreWeave capacity already billing ahead of schedule, average annualized GAAP colocation revenue running at approximately $635 million based on management figures, AMD initial delivery expected in H1 2027, and management explicitly planning to fund the roughly $6 billion AMD build-out through project-level bonds rather than dilutive equity. That is a serious cash flow machine if execution holds.

On the bearish side: the company issued $3.3 billion in 7.75% Senior Secured Notes due 2031 to fund expansion, total debt is substantial, free cash flow is deeply negative during the construction phase, and one customer currently represents the dominant share of colocation revenue. If the CoreWeave relationship encounters friction before AMD capacity comes online in 2027, the revenue trajectory changes materially. That is the event the put side of the market is hedging.

The implied move on CORZ around major catalysts has been running in the 15 to 20% range. With a 5.50 beta, that is consistent. What matters is that the AMD warrant vesting schedule and CoreWeave delivery milestones function as embedded binary events inside what looks from a chart perspective like a flat, directionless stock. They are not flat events. Each construction milestone is a mini-catalyst with real revenue implications.

Strategic Considerations

The elevated IV30 environment post-earnings creates a specific options landscape. Implied volatility above the 52-week median means option premiums are relatively rich. That changes the risk/reward calculus depending on directional conviction.

For traders who believe execution on the CoreWeave ramp and AMD timeline continues on schedule: a defined-risk call spread in the October-to-November timeframe captures the thesis with a ceiling on premium paid. The $22/$28 call spread, for example, gives exposure to the analyst consensus range while limiting total risk to the debit paid. Paying elevated premium for outright long calls in a high-IV environment means time decay works against the position from day one. A vertical spread neutralizes some of that theta drag while keeping the directional exposure intact.

For traders focused on execution risk and debt overhang: a defined-risk put spread targeting the $16 to $18 range captures the downside scenario if construction delays or bond financing friction emerge before AMD’s H1 2027 initial delivery. The $20/$16 put spread defines maximum risk while expressing a view that the current support level is not structural given the leverage on the balance sheet.

For traders who believe the stock oscillates between $18 and $25 until the next hard catalyst, a short iron condor centered on the current range collects premium from the elevated IV environment while defining risk on both wings. The logic: if the market genuinely cannot decide whether CORZ is a $15 miner or a $35 AI platform, it may stay range-bound until a specific delivery milestone forces a re-evaluation. Collecting premium while that uncertainty resolves is a legitimate neutral posture.

What I would avoid: naked directional bets on a 5.50 beta stock with elevated IV and binary catalysts on the horizon. The move sizing matters as much as the direction. This is not the instrument for undisciplined position sizing.

What to Watch

• AMD initial megawatt delivery at Pecos, Texas, the lead site, expected H1 2027. Any announcement accelerating or delaying that timeline will move IV and the underlying simultaneously. Watch for press releases, 8-K filings, or management commentary at investor conferences between now and year-end.
• CoreWeave final 150 megawatt delivery at Dalton Phase II, on track for early 2027. This completes the original CoreWeave contract. Confirmation closes the customer concentration risk for the existing business. A delay would widen put skew quickly.
• Project-level bond financing for the AMD build-out. Management has guided toward this structure to protect equity holders from dilution. If bond markets tighten or terms deteriorate, the equity story changes. Watch credit spreads in the data center infrastructure space as a leading indicator.
• A third anchor customer announcement. Over 2 gigawatts of new site opportunities are reportedly under due diligence. Any signed LOI or lease agreement would reset the customer concentration discussion and likely spike IV as traders reprice the growth trajectory.
• Self-mining wind-down completion by year-end 2026. Once Bitcoin mining clears the books entirely, the GAAP presentation simplifies and year-over-year comparisons become clean. This is when screener-driven investors who have been filtering out CORZ on GAAP losses may begin re-examining the stock. That is a potential IV compression event on the call side.
• IV behavior ahead of Q3 earnings, expected around late October or early November. With AMD initial delivery beginning in H1 2027, Q3 will be the last quarter before the next revenue inflection. Watch whether IV runs higher into that report than it did into Q2. If it does, the market is pricing in a larger expected move, which may favor spreads over outright premium buying.

What the options market is saying right now is this: the participants buying calls at 55% above average volume on a down day do not believe this is a miner in decline. They believe it is an AI infrastructure platform that has not yet been priced as one. The participants selling puts at the $25 strike with premiums running at elevated levels are either hedging long equity or expressing a view that the downside is capped by $24 billion in contracted backlog.

Neither side is wrong about the facts. They are disagreeing about the timing. That is exactly the kind of market disagreement that options positioning reveals before it becomes visible in the stock price itself.

The next hard catalyst is AMD’s H1 2027 initial delivery at Pecos. Between now and then, the options market will keep repricing the probability of that event on schedule. Watch the IV curve, watch the put/call ratio, and watch whether call spread activity in the October-to-January range continues to build. That is the real read on where institutional conviction is pointing.